Posters

      Comparison of the biological impact of cigarette smoke and a prototypic modified risk tobacco product on human versus rat primary normal bronchial epithelial cells

      Kogel, U.; Poussin, C.; Messinis , D. E.; Frentzel, S.; Gonzalez-Suarez, I.; Martin, F.; Mathis, C.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Nov 9, 2014
      Conference name
      American College of Toxicology (ACT) 2014
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.